4.7 Review

The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer

Journal

FRONTIERS IN ENDOCRINOLOGY
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2021.687244

Keywords

neoadjuvant endocrine therapy; breast cancer; Ki67; hormone-positive breast cancer; clinical marker

Funding

  1. National Natural Science Foundation of China [81972791]

Ask authors/readers for more resources

Ki67, a proliferation marker, is proposed for breast cancer subtype classification, prognosis, and therapeutic response prediction. However, its questionable analytical validity hinders its widespread adoption in treatment decisions for breast cancer. Studies have shown potential for Ki67 as a predictive marker in neoadjuvant endocrine therapy.
Ki67 is a proliferation marker. It has been proposed as a useful clinical marker for breast cancer subtype classification, prognosis, and prediction of therapeutic response. But the questionable analytical validity of Ki67 prevents its widespread adoption of these measures for treatment decisions in breast cancer. Currently, Ki67 has been tested as a predictive marker for chemotherapy using clinical and pathological response as endpoints in neoadjuvant endocrine therapy. Ki67 can be used as a predictor to evaluate the recurrence-free survival rate of patients, or its change can be used to predict the preoperative window of opportunity in neoadjuvant endocrine therapy. In this review, we will elaborate on the role of Ki67 in neoadjuvant endocrine therapy in breast cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available